NCM
TMO icon

Novare Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Novare Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2M Sell
24,739
-637
-3% -$346K 0.96% 36
2025
Q4 		$14.7M Buy
25,376
+101
+0.4% +$57.1K 1.1% 27
2025
Q3 		$12.3M Buy
25,275
+779
+3% +$363K 0.93% 37
2025
Q2 		$9.93M Buy
24,496
+1,834
+8% +$767K 0.81% 43
2025
Q1 		$11.3M Sell
22,662
-853
-4% -$462K 0.99% 41
2024
Q4 		$12.2M Buy
23,515
+490
+2% +$269K 1.03% 33
2024
Q3 		$14.2M Buy
23,025
+105
+0.5% +$62.2K 1.21% 21
2024
Q2 		$12.7M Sell
22,920
-408
-2% -$234K 1.14% 25
2024
Q1 		$13.6M Buy
23,328
+804
+4% +$451K 1.23% 24
2023
Q4 		$12M Buy
22,524
+1,430
+7% +$692K 1.22% 23
2023
Q3 		$10.7M Buy
21,094
+719
+4% +$383K 1.2% 23
2023
Q2 		$10.6M Buy
20,375
+193
+1% +$104K 1.14% 25
2023
Q1 		$11.6M Sell
20,182
-234
-1% -$132K 1.32% 20
2022
Q4 		$11.2M Buy
20,416
+90
+0.4% +$47.7K 1.33% 19
2022
Q3 		$10.3M Sell
20,326
-263
-1% -$147K 1.32% 18
2022
Q2 		$11.2M Sell
20,589
-383
-2% -$211K 1.38% 18
2022
Q1 		$12.4M Sell
20,972
-1,524
-7% -$875K 1.32% 19
2021
Q4 		$15M Sell
22,496
-677
-3% -$423K 1.52% 15
2021
Q3 		$13.2M Sell
23,173
-676
-3% -$371K 1.47% 17
2021
Q2 		$12M Buy
23,849
+450
+2% +$212K 1.34% 21
2021
Q1 		$10.7M Buy
23,399
+352
+2% +$168K 1.29% 25
2020
Q4 		$10.7M Sell
23,047
-1,538
-6% -$721K 1.4% 19
2020
Q3 		$10.9M Sell
24,585
-1,968
-7% -$813K 1.53% 15
2020
Q2 		$9.62M Sell
26,553
-1,379
-5% -$462K 1.44% 17
2020
Q1 		$7.92M Sell
27,932
-997
-3% -$314K 1.39% 18
2019
Q4 		$9.4M Sell
28,929
-178
-0.6% -$54K 1.31% 20
2019
Q3 		$8.48M Sell
29,107
-1,652
-5% -$473K 1.26% 23
2019
Q2 		$9.03M Sell
30,759
-1,371
-4% -$378K 1.38% 19
2019
Q1 		$8.79M Sell
32,130
-2,069
-6% -$515K 1.37% 20
2018
Q4 		$7.65M Sell
34,199
-1,185
-3% -$278K 1.4% 20
2018
Q3 		$8.64M Sell
35,384
-360
-1% -$82.8K 1.38% 21
2018
Q2 		$7.4M Sell
35,744
-668
-2% -$142K 1.26% 26
2018
Q1 		$7.52M Buy
36,412
+395
+1% +$82.9K 1.32% 18
2017
Q4 		$6.84M Sell
36,017
-256
-0.7% -$49K 1.16% 28
2017
Q3 		$6.86M Sell
36,273
-670
-2% -$121K 1.21% 26
2017
Q2 		$6.45M Sell
36,943
-685
-2% -$115K 1.45% 26
2017
Q1 		$5.78M Buy
37,628
+340
+0.9% +$52K 1.34% 29
2016
Q4 		$5.26M Buy
37,288
+2,860
+8% +$422K 1.29% 29
2016
Q3 		$5.48M Buy
34,428
+1,300
+4% +$200K 1.43% 24
2016
Q2 		$4.89M Sell
33,128
-50
-0.2% -$7.38K 1.32% 28
2016
Q1 		$4.7M Sell
33,178
-7,640
-19% -$1.02M 1.32% 30
2015
Q4 		$5.79M Buy
40,818
+15,460
+61% +$2.06M 1.58% 22
2015
Q3 		$3.1M Buy
25,358
+17,240
+212% +$2.25M 0.85% 52
2015
Q2 		$1.05M Hold
8,118
– – 0.26% 78
2015
Q1 		$1.09M Hold
8,118
– – 0.27% 75
2014
Q4 		$1.02M Hold
8,118
– – 0.25% 80
2014
Q3 		$988K Hold
8,118
– – 0.24% 83
2014
Q2 		$958K Hold
8,118
– – 0.23% 85
2014
Q1 		$976K Hold
8,118
– – 0.26% 81
2013
Q4 		$904K Hold
8,118
– – 0.25% 84
2013
Q3 		$748K Sell
8,118
-182
-2% -$16.5K 0.23% 83
2013
Q2 		$702K Buy
+8,300
New +$691K 0.24% 83

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Novare Capital Management's TMO Position: Q1 2026 in Review

Novare Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 2.5% in Q1 2026, selling an estimated $346K and leaving 24,739 shares worth $12.2M. The position accounts for 0.96% of the portfolio, ranked #36.

Novare Capital Management first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $15M in Q4 2021. 2,589 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Novare Capital Management held 24,739 shares of Thermo Fisher Scientific worth $12.2M as of Q1 2026.
  • Novare Capital Management sold 637 Thermo Fisher Scientific shares in Q1 2026, an estimated $346K.
  • Thermo Fisher Scientific made up 0.96% of Novare Capital Management's portfolio in Q1 2026, its #36 holding.
  • Novare Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Novare Capital Management's Thermo Fisher Scientific position peaked at $15M in Q4 2021.
  • 2,589 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Novare Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.